The expression and clinical significance of FLT3/ITD gene mutation in hematologic malignancies
- VernacularTitle:血液肿瘤患者FLT3/ITD基因突变的检测及临床意义
- Author:
Bing XU
;
Jiahong TANG
;
Lin LI
- Publication Type:Journal Article
- Keywords:
Hematologic neoplasms;
FLT3/ITD mutation;
Polymerase chain reaction;
Prognosis
- From:
Chinese Journal of Practical Internal Medicine
2006;0(14):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore Fms-like tyrosine kinase 3(FLT3)gene internal-tandem duplications(ITD)mutation in hematologic malignancy.Methods FLT3/ITD gene mutation was analyzed by polymerase chain reaction(PCR)amplification on the DNA samples from 332 patients with hematologic malignancies at the Nanfang Hospital from 2001 to 2005.Results The mutation of FLT3/ITD gene was detected in 22.3% acute myeloid leukemia(AML)cases,in 6.5% chronic myeloid leukemia(CML)-blast crisis(BC)cases,in 5.6% myelodysplastic syndromes(MDS)cases and in 2.6% acute lymphoblastic leukemia(ALL)cases;FLT3/ITD gene mutation was not detected in CML-chronic phase(CP),multiple myeloma(MM),non-Hodgkin lymphoma(NHL)and chronic lymphocytic leukemia(CLL)cases.FLT3/ITD+ AML indicate high white blood cell count and high percentage of bone marrow blast cells and had a unfavourable cumulative relapse rates.Conclusion AML patients with FLT3/ITD have a poor prognosis.Detection of FLT3/ITD gene mutation may be valuable in hematologic malignancy.
